EyePoint awarded 2 U.S. patents related to Dexycu
EyePoint Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued Notices of Allowance for two patents covering Dexycu, the company's FDA-approved long-acting intraocular product for the treatment of postoperative inflammation. The first patent includes claims relating to a method of treating inflammation of an eye following cataract surgery by delivering extremely small amounts of dexamethasone in triethyl acetyl citrate. Once issued, this patent will expire in 2034. The second patent includes claims relating to loading and delivering a small dose volume from an injection syringe. Once issued, this patent will expire in 2032.